Sale!

ISSECAM iVZW PROSCA & BLADDR 2022

35 $

‘+ Include: 26 videos + 1 pdf, size: 17.8 GB

+ Target Audience: surgerist, nephrologist

Description

+ Include: 26 videos + 1 pdf, size: 17.8 GB

+ Target Audience: surgerist, nephrologist

+ Sample video: contact me for sample video

+ Information:

No

 

 

+ Topics:

1.PROSCA_2022-OFFICIAL OPENING.mp4
2.PROSCA_2022-DAY 1-S1 APCCC 2022 HIGHLIGHTS.mp4
3.PROSCA_2022-DAY 1-S2 MANAGEMENT OF INTERMEDIATE RISK PCa.mp4
4.PROSCA_2022-DAY 1-S3 FOLLOW-UP AFTER RADICAL THERAPY.mp4
5.PROSCA_2022-DAY 1-BEST POSTER SESSION.mp4
6.PROSCA_2022-DAY 1-UPDATE LECTURE AR ANTAGONISTS, ARE THEY ALL EQUAL.mp4
7.PROSCA_2022-DAY 1-S4 HIGH RISK AND VERY HIGH RISK PCa.mp4
8.PROSCA 2022-DAY 2-S5 EVOLVING STRATEGIES IN mHSPC.mp4
9.PROSCA 2022-DAY 2-UPDATE LECTURE LATEST TECHNIQUES AND DEVELOPMENTS IN SURGERY.mp4
10.PROSCA 2022-DAY 2-NEW CONCEPTS IN PCa PATHOLOGY.mp4
11.PROSCA 2022-DAY 2-S6 OPTIMAL STRATEGIES FOR PATIENTS PROGRESSING ON AR-PATHWAY INHIBITORS.mp4
12.PROSCA 2022-DAY 2-S7 OLIGORECURRENT HSPC.mp4
13.PROSCA 2022-DAY 2-S8 BACK TO THE FUTURE-10 YEARS OF PROSCA.mp4
14.PROSCA 2022-DAY 2-UPDATE LECTURE-IMMUNOTHERAPY IN PROSTATE CANCER.mp4
15.PROSCA 2022-DAY 2-S9 PROSCA MEETS BLADDR SESSION.mp4
16.BLADDR 2022-DAY 1-OFFICIAL OPENING.mp4
17.BLADDR 2022-DAY 1-S1 BLADDER PRESERVATION STRATEGIES.mp4
18.BLADDR 2022-DAY 1-S2 STAGING AND FOLLOW-UP OF PATIENTS WITH NON-METASTATIC DISEASE.mp4
19.BLADDR 2022-DAY 1-S3 METASTATIC UCa.mp4
20.BLADDR 2022-DAY 1-S4 RC WITH ILEAL CONDUIT-LESSONS TO BE LEARNED.mp4
21.BLADDR 2022-DAY 1-MULTIDISCIPLINARY MANAGEMENT OF PATIENTS WITH MIBC.mp4
22.BLADDR 2022-DAY 1-S5 MOLECULAR BIOMARKERS.mp4
23.BLADDR 2022-DAY 1-S6 LOCAL DISEASE MANAGEMENT.mp4
24.BLADDR 2022-DAY 2-BEST POSTER SESSION.mp4
25.BLADDR 2022-DAY 2-S7 PERIOPERATIVE SYSTEMIC THERAPIES.mp4
26.BLADDR 2022-DAY 2-CHALLENGING DILEMMAS IN CLINICAL PRACTISE AND RESEARCH.mp4
Program.pdf

Reviews

There are no reviews yet.

Be the first to review “ISSECAM iVZW PROSCA & BLADDR 2022”

Your email address will not be published. Required fields are marked *